Table 4 |
|||||
|
Summary of clinical outcomes stratified by group. |
|||||
|
Outcome |
Total (n = 145) |
AML ICU Cases (n = 45) |
AML non-ICU Controls (n = 50) |
Non-AML ICU Controls (n = 225) |
p-value |
|
|
|||||
|
ICU death (%) |
83 (30.7) |
17 (37.8) |
- |
66 (29.3) |
0.29 |
|
|
|||||
|
Hospital death (%) |
121 (37.8) |
20 (44.4) |
9 (18.0) |
92 (40.9) |
0.004 |
|
|
|||||
|
28-Day death (%) |
98 (30.6) |
17 (37.8) |
8 (16.0) |
73 (32.4) |
0.03 |
|
|
|||||
|
90-Day death (%) |
132 (41.3) |
23 (51.1) |
16 (32.0) |
93 (41.3) |
0.17 |
|
|
|||||
|
1-Year death (%) |
178 (55.6) |
32 (71.1) |
27 (54.0) |
119 (52.9) |
0.08 |
|
|
|||||
|
ICU length of stay (days) |
4 (2-11) |
5 (2-12) |
- |
4 (2-11) |
0.38 |
|
|
|||||
|
Survived |
5 (2-12) |
8 (2-14) |
- |
5 (3-11) |
0.44 |
|
Dead |
2 (1-5) |
4 (1-7) |
- |
1 (1-3) |
0.17 |
|
|
|||||
|
Hospital length of stay (days) |
15 (6-39) |
22 (11-47) |
24 (9-35) |
13 (5-36) |
0.12 |
|
Survived |
21 (10-45) |
37 (18-50) |
25 (12-35) |
17 (10-44) |
0.22 |
|
Dead |
14 (9-28) |
13 (9-19) |
6 (1-28) |
3 (1-12) |
0.17 |
|
|
|||||
|
Median survival (95% CI) (days) |
207 (14-2442) |
82 (14-700) |
274 (55-1303) |
258 (9-2442) |
0.01 |
|
|
|||||
|
Roze des Ordons et al. BMC Cancer 2010 10:516 doi:10.1186/1471-2407-10-516 |
|||||
